Inlyta

Could Pfizer’s Inlyta have a role in Alzheimer’s disease?
Could Pfizer’s Inlyta have a role in Alzheimer’s disease?
Pharmaforum
Pfizer
Inlyta
Alzheimer's disease
Flag link:
Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Pharmaforum
Merck KGaA
Pfizer
Bavencio
FDA
Inlyta
advanced renal cell carcinoma
Flag link:
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Xconomy
Merck
FDA
Keytruda
kidney cancer
advanced renal cell carcinoma
Inlyta
Flag link:
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Motley Fool
Pfizer
Inlyta
kidney cancer
Merck
Keytruda
Flag link:
Merck, Pfizer drug combo extends kidney cancer survival -study
Merck, Pfizer drug combo extends kidney cancer survival -study
Yahoo/Reuters
Merck
Pfizer
kidney cancer
Keytruda
Inlyta
Sutent
Flag link:
Keytruda-Inlyta combo under Priority Review for first-line RCC
Keytruda-Inlyta combo under Priority Review for first-line RCC
BioCentury
Merck
Keytruda
Inlyta
renal cell carcinoma
FDA
priority review
Flag link:
Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win
Fierce Pharma
Merck
Keytruda
kidney cancer
Pfizer
Inlyta
Sutent
Flag link:
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer
Merck KGaA, Pfizer's immuno-drug shown to alleviate kidney cancer
Yahoo/Reuters
Merck KGaA
Bavencio
Pfizer
kidney cancer
Inlyta
Flag link:
Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure
Pfizer strikes out on Inlyta expansion bid with postsurgery kidney cancer failure
Fierce Pharma
Pfizer
renal cell carcinoma
kidney cancer
Inlyta
Flag link:
Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
CP Wire
Pfizer
renal cell carcinoma
Inlyta
Flag link:
Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery
Pfizer
renal cell carcinoma
Inlyta
Flag link:
Pfizer Has Strong Track Record since 2010
Pfizer Has Strong Track Record since 2010
Market Realist
Pfizer
drug approvals
Ibrance
Prevnar 13
Inlyta
Xalkori
Xeljanz
Flag link:
Pfizer’s Pipeline Story Begins to Unravel
Pfizer’s Pipeline Story Begins to Unravel
Yahoo/YCharts
Pfizer
Eliquis
Xalkori
Xeljanz
Inlyta
Elelyso
Flag link:
Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players
Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players
Motley Fool
kidney cancer
ONYX Pharmaceuticals
Bayer
Nexavar
Roche
Avastin
Inlyta
Sutent
Pfizer
Votrient
GSK
Afinitor
Novartis
BMS-936558
Bristol-Myers Squibb
tivozanib
Aveo Oncology
Flag link:
Pfizer cancer pill Inlyta gets EU approval for kidney cancer after failure of first treatment
Pfizer cancer pill Inlyta gets EU approval for kidney cancer after failure of first treatment
Yahoo/AP
Pfizer
kidney cancer
Inlyta
Europe
Flag link:
Pfizer says EU advisory panel recommends approval for its advanced kidney cancer drug Inlyta
Pfizer says EU advisory panel recommends approval for its advanced kidney cancer drug Inlyta
Yahoo/AP
Inlyta
Pfizer
Europe
kidney cancer
Flag link:
FDA clears Pfizer drug for advanced kidney cancer
FDA clears Pfizer drug for advanced kidney cancer
Yahoo/AP
Pfizer
kidney cancer
renal cell carcinoma
Inlyta
Flag link: